As the Nasdaq wobbles on capex, this Buffett strategy went 15-for-15

InvestingPro’s Best of Buffett strategy reported a 100% win rate in October to date and a 7.86% average return across its selections. Nucor gained 15.18% in October, supported by record Q2 shipments of 7.1 million tons and $829 million in quarterly free cash flow; UnitedHealth rose 11.47% after adjusted Q3 EPS of $4.69 beat consensus by 13.8% and full-year profit guidance was raised to at least $20.50 per share. The article frames cash-generative, defensive companies as resilient amid elevated borrowing costs and scrutiny of Big Tech’s AI spending, while citing a 31.5% modeled upside for UnitedHealth.

Analysis

The article’s stronger investable signal is a possible rotation toward cash-generative cyclicals—not evidence that either stock is insulated from risk. For Nucor, data-center and grid construction could support orders, but the return depends on steel pricing, mill utilization, and input costs, not project announcements alone. Hyperscale construction is only one source of demand; if projects slip or steel supply expands, the capex narrative may not protect earnings. After a sharp reported run, valuation claims based on forward estimates warrant independent verification before adding exposure. The key 1–3 month checks are order/backlog commentary, realized pricing, and guidance; over 6–18 months, project execution and capacity additions matter more than AI headlines.

UnitedHealth’s cash generation does not make it a pure rate or macro hedge. Medical-cost trends, government reimbursement decisions, and Optum execution can overwhelm defensive demand; the reported earnings beat should be tested against underlying claims experience and updated guidance. Near term, this is a catalyst-driven earnings-quality question, not simply a duration trade.

The promotional strategy’s October win rate and backtested selection performance are not evidence of repeatable alpha; quarterly 13-F disclosures are lagged and do not show current positioning. Contrarian risk: investors may be over-attributing steel demand to AI while underpricing the policy and medical-cost sensitivity in managed care. No precise valuation conclusion is supportable from the article alone.

Key Decisions for Investors

• NUE: Avoid chasing the reported rally. Consider staged exposure only on a pullback, contingent on confirmation in order trends, realized steel prices, and margins. Falsify the thesis on weakening order/backlog commentary or guidance reductions; track scrap and energy costs as margin risks.
• Relative-value watch: If seeking a narrower expression of company-specific execution, evaluate long NUE versus a steel-sector basket such as SLX, with beta and sector exposures sized deliberately. Do not initiate solely on the AI-buildout narrative; reassess if NUE’s operating performance fails to outperform the basket.
• UNH: Keep on a catalyst watch rather than treating it as an automatic defensive long. Verify medical-cost trends, reimbursement outlook, and Optum performance in company disclosures. A deterioration in cost trends or a guidance reset would falsify the earnings-recovery case.
• Discount the article’s strategy-performance claims until methodology, selection dates, turnover, and benchmark-relative returns are independently verified; 13-F-based signals are inherently delayed.